Innovation Grants support the highest quality creative problem solving in cancer research. The goal of the Innovation program is to support the development and testing of transformative, paradigm-shifting concepts and approaches to address problems in cancer research, enhance our understanding of cancer, and generate novel approaches to confront the challenges we face in defeating cancer.
Budgets awarded may be up to $100,000 per year and a maximum of $200,000 per grant.
It is anticipated that approximately 30 grants will be awarded in this competition.
Please note the following:
- Full application deadline: October 15, 2019
- This competition consists of a full application only, abstract registration is not required
- There must be no (0%) overlap with any pending or held grant applications (i.e. 100% unique aims are required – conceptual overlap is acceptable but must be described by the applicant)
Special funding calls within the Innovation Grant competition envelope:
- Applications relevant to breast cancer research are encouraged
- Applications relevant to skin cancer are encouraged
- As a result of a generous donation, funding for one application with a focus on early detection, diagnosis, and/or treatment of malignant mixed Müllerian tumours (MMMT) is available
- Additional funds may be available from the Lotte and John Hecht Memorial Foundation to support innovative projects focused on the application of complementary and alternative approaches in cancer treatment and control
Innovation to Impact Grants
Please note that only investigators with a funded Innovation or CBCF research grant with a project end date between January 1, 2017 and April 30, 2020 are eligible for this program. These grants are intended to support the next phase following a productive CCS Innovation Grant or CBCF research grant, with the goal of working towards or achieving a significant impact on cancer.
Full application deadline: October 15, 2019
Canadian Cancer Society travel awards for PhD, MD, MD/PhD students, and post-doctoral/medical/clinical fellows
These awards are intended to defray the travel costs associated with making a scientific presentation as a first author or presenter at a conference, symposium or other appropriate professional meeting. PhD, MD, or MD/PhD students, and post-doctoral/medical/clinical fellows are eligible to apply.
There are three competitions in 2019. It is anticipated that approximately 10 Travel Awards will be awarded in each competition (approximately 30 awards per year).
Please note the following:
- Applications will only be accepted for conference dates within 6 months following the funding start date.
- Eligible expenses include: 1) Conference registration fees; 2) Accommodations; and 3) Transportation, and will not exceed $2,000.
- Individuals may receive this award only once per stage of training (PhD, MD, Post-doctoral fellow). Unsuccessful applicants may reapply in subsequent competitions.
- Full application deadline: September 15, 2019
Travel Awards for PhD and MD/PhD students and post-doctoral/medical/clinical fellows [next due date 15-May-2019]
The Travel Awards program to support PhD or MD/PhD students and post-doctoral/medical/clinical fellows to present data at a conference, symposium or other appropriate professional meeting will be launched April 1st for the May 15, 2019 deadline.
There are normally three competitions each year:
|1st Competition||2nd Competition||3rd Competition|
|Funding start |
|April 1||August 1||December 1|
For those seeking support to attend the Canadian Cancer Research Conference in Ottawa in November this year, please apply for funding during this round (see eligible conference dates for this program).
The Canadian Institutes of Health Research Institute of Cancer Research (ICR) and Institute of Neurosciences, Mental Health and Addiction (INMHA), in partnership with the Canadian Cancer Society, will support Research investigating the benefits and/or harms related to therapeutic use of cannabis in people living with cancer.
See CIHR grant page HERE
The Cannabis Research in Priority Areas Team Grants is expected to:
- •Generate new scientific knowledge that will advance our understanding of the potential benefits and/or harms of cannabis and/or cannabis use, and impact policies and programs in this area
- Encourage interdisciplinary collaborations, including from across health research and from domains outside of health research, and the sharing of data and resources
- Enhancing capacity development and training in cannabis research
- Connect to existing knowledge translation efforts across Canada, for example through MHCC or the Canadian Centre on Substance Use and Addiction (CCSA)
The maximum amount per grant is $300,000 per year for up to 5 years for a total of $1.5 million, per grant. $1.5 million is available to fund an application relevant to the Cancer Pool (sponsored by the Canadian Cancer Society, ICR, and INMHA).
LOI due date: May 15, 2019
LOI notice of decision: July 15, 2019
Full application deadline: October 8, 2019
Funding start date: January 1, 2020
All applications must be submitted through CIHR’s ResearchNet. For more information view the funding opportunity details on the CIHR website.
CIHR will be hosting webinar(s) to review with participants the requirements of this funding opportunity and to answer questions. To find out more information and to register, visit the Webinars page.
The goal of the CCS/CIHR Cancer Survivorship Team Grant program is to improve the health outcomes for cancer survivors of all ages (pediatric, adolescent, young adult and adult) from the time of their cancer diagnosis until the time of their death or entry into palliative care. This program is not intended to focus on improving end-of-life care.
The intent of this funding opportunity is to support new intervention research designed to mitigate the challenges experienced along the survivorship journey, as well as the evaluation and validation of existing interventions to assess their potential for implementation as best practices.
The program goal will be achieved through the support of a network of multidisciplinary teams, each led by a nominated Principal Investigator and at least 2 co-Principal and/or co- Investigators, one of whom must be within their first five years as an independent researcher, drawn from at least 3 different regions of Canada (Atlantic Provinces, Central Canada, Prairie Provinces, West Coast, Northern Territories). Survivors and caregivers are expected to be engaged as full and active members of research teams.
Teams may request up to $500,000 per year for a maximum of $2,500,000 over a five-year period. Grants will be non-renewable. As the total budget for this competition is $10 million, it is anticipated that at least 4 teams will be funded in this competition. The engagement of additional partners may increase this number.
Registration due date: May 29, 2019
Relevance review results: mid-June, 2019
Full application deadline: September 10, 2019
Results announcement : November 2019
Anticipated start date: December 1, 2019
All applications must be submitted through the online application system (EGrAMS) by 5p.m. EST on the deadline date. Submissions will not be accepted beyond these times.
A Webinar is planned to explain the application process and overall objectives of the call. Applicants can register by sending an email at firstname.lastname@example.org. Details for the April 8th, 2019 (@1pm EST) webinar will be provided in advance to interested applicants.
BioCanRx Call for Letter of Intent – Bench to Bedside Translation of Innovative Cancer Biotherapeutics
Bench to Bedside Translation of Innovative Cancer Biotherapeutics
BioCanRx, Canada’s Immunotherapy Network, is pleased to announce its 2019 Call for Letters of Intent. Selected Letters of Intent will be featured in the Scientific Program of our Cycle II application going forward for review in July 2019 to the federal government’s Networks of Centres of Excellence (NCE) Program.
Building on previous BioCanRx investments in Cycle I, the overarching goal of the Cycle II Research Program will focus on extending immunotherapy successes in the clinic beyond initial responders. To address this challenge, while making use of technologies in the BioCanRx pipeline or by soliciting new complimentary technology, BioCanRx will invest in projects aimed at understanding patient and/or tumour type limitation(s) and proposing improved novel therapies, trials, or combination approaches to overcome the identified limitation(s)
Applications must be received by Wednesday, May 1, 2019.
Full details at https://biocanrx.com/research/research-program-renewal
THE CANCER RESEARCH SOCIETY IS PLEASED TO ANNOUNCE A NEW FUNDING PROGRAM: Translational Research Partnership Program
*** Pour le français, voir plus bas ***
THE CANCER RESEARCH SOCIETY IS PLEASED TO ANNOUNCE A NEW FUNDING PROGRAM
Translational Research Partnership Program
In addition to its regular funding programs, the Cancer Research Society is pleased to support high-impact translational projects throughout Canada. Our aim is to work in collaboration with partners to co-fund bold research projects in order to accelerate the development of new and innovative treatments or medical devices for the benefit of patients.
For more information on this new program, we invite you to visit our website: https://www.societederecherchesurlecancer.ca/en/researchers/translational-research-partnership
Programme de partenariat de recherche translationnelle
Programme de partenariat de recherche translationnelle
En plus de ses programmes de financement réguliers, la Société de recherche sur le cancer a plaisir d’appuyer des projets de recherche translationnelle à haut impact au Canada. L’objectif est de travailler en collaboration avec des partenaires pour cofinancer des projets de recherche audacieux afin d’accélérer le développement de nouvelles approches thérapeutiques ou de technologies médicales innovantes au bénéfice des patients.
Pour plus d’information sur ce nouveau programme, nous vous invitons à consulter notre site web. https://www.societederecherchesurlecancer.ca/fr/chercheurs/partenariat-de-recherche-translationnelle
Scholarships for the Next Generation of Scientists Competition [$50,000 PDF + $120,000 operating grant]
Please forward this message to all postdoctoral fellows interested in pursuing a career in cancer research in Canada.
The Cancer Research Society is pleased to announce the launch of its 2019 Scholarships for the Next Generation of Scientists competition, an initiative aiming at supporting future generations of Canadian researchers. The Scholarship is broken down into two parts, and extends over a period of 3 years, with no possibility for renewal.
Deadlines for submitting an application: April 26, 2019, 11:59 pm (EST).
Part 1: Postdoctoral Salary Award – 1 year * – $50,000 One year postdoctoral salary award for a candidate finishing his/her fellowship. The candidate must have completed at least two years of postdoctoral training at the time he/she accepts the salary award.
* Possibility of extending Part 1 of this award for a maximum period of 6 months.
Part 2: Operating Grant – 2 years – $120,000 ($60,000/year) Operating grant award once the candidate has obtained a faculty position at a recognized Canadian institution.
You have two options for submitting your application.
- Sending your application and accompanying documents using the button provided on our website. The deadline for submitting your electronic files is April 26 2019, 11:59 pm (EST).
- Saving on two (2) CDs or two (2) USB keys and sending it by mail or courier, as per the instructions on our website. The deadline for mailing your application is April 26, 2019. Applications must be postmarked on or before this date.
For additional information on the competition, please visit our website.
For all questions, please contact Lucille Beaudet or Irina Navarrete at email@example.com or, toll free, 1 888-766-2262.
Lucille BeaudetDirector, Scientific Affairs
Attention Brain Tumor Researchers! Funding opportunity “Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors”. LOI due 15-Feb-2019 and 15-Dec-2019
NCI is now accepting applications for the funding opportunity “Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors” (RFA-CA-19-033**).
The full request for applications (RFA) is available here.
This RFA aims to develop and test interventions that prevent, mitigate, or manage adverse outcomes in pediatric and/or AYA cancer survivors and/or evaluate models of care that strengthen coordination, continuity, and quality, or that reduce access barriers to needed services including follow-up care, and that improve outcomes across the survivor’s lifespan.
This RFA is associated with the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act of 2018 that is intended to maximize and accelerate discovery, development, and availability of promising childhood cancer treatments. National Brain Tumor Society (NBTS) is proud to be one of a handful of pediatric cancer organizations who convened to identify, coordinate, and prioritize the needs of the pediatric cancer population which led to the STAR Act.
Applications are encouraged that address any of the following areas relevant to pediatric and AYA cancer survivors, as outlined in the STAR Act:
- Outcomes and/or Barriers to follow-up care, including within minority or other medically underserved populations and with respect to health disparities
- The impact of relevant factors, which may include familial, socioeconomic, and other environmental factors, on treatment outcomes and survivorship
- The development of indicators used for long-term follow-up and analysis of the late effects of cancer treatment
- The identification of risk factors associated with late effects of treatment; predictors of adverse neurocognitive and psychosocial outcomes; and the molecular basis of long-term and late complications
- The development of targeted interventions to reduce the burden of morbidity borne by cancer survivors to protect such cancer survivors from the late effects of cancer or its treatment
Working with our brain tumor advocates, NBTS coordinated hundreds of meetings with congressional offices to share the importance of this bill and encourage Member support. Because of the devoted efforts from volunteer advocates, and the collaboration across many pediatric cancer organizations, the STAR Act became law in record time and will have a lasting impact on the pediatric brain tumor population.
Thank you for your ongoing dedication to the needs of brain tumor patients and their families.
National Brain Tumor Staff and Board
** RFA-CA-19-033 is also associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research.
CADTH Symposium Travel Award Program for Students and Patient Group Representatives – apply by 10-Dec-2018
CADTH is pleased to announce the 2019 CADTH Symposium Travel Award Program for students and patient group representatives.
Since 2007, CADTH has provided financial support toward conference-related costs for more than 335 student and patient group representatives as part of our commitment to making this important event accessible to all health care stakeholders.
This year, eligible students and patient group representatives can receive up to $2,000 to offset registration, travel, food, accommodation, and other conference-related expenses.
The 2019 CADTH Symposium offers an excellent opportunity to share your research, learn about the latest advancements in health technology assessment, and interact with peers from across the country as well as leading Canadian and international experts. If you’re a full-time undergraduate or graduate student attending a degree-granting institution in Canada, and taking courses in a field relevant to CADTH’s work, we invite you to apply for a travel award.
For Patient Group Representatives
It’s important that your voice is heard. If you work for a not-for-profit, patient-related organization, or a citizen’s organization interested in health policy, we invite you to apply for a travel award.
How to Apply
Step 1: Review the 2019 CADTH Symposium Travel Award Program Criteria.
Step 2: Complete and submit the 2019 Travel Awards Application form to CADTH by December 10, 2018.
Travel award decisions will be made by the end of January 2019, and awards will be issued to successful applicants by the end of March 2019.
Reminder: The Abstract Submission Deadline for the 2019 CADTH Symposium is October 26, 2018. Priority will be given to Travel Award applicants who have submitted an abstract for the 2019 CADTH Symposium.
If you have questions about the 2019 CADTH Symposium, or the Travel Award Program, please contact us at firstname.lastname@example.org. We’re looking forward to seeing you in Edmonton in 2019.
CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system. CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Learn more at: www.cadth.ca.